Drugs that contain Semaglutide

1. Drug name - OZEMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(9 years from now)

CN101133082A NOVO Acylated Glp-1 Compound
Mar, 2026

(3 years from now)

CN101133082B NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

IN262697B NOVO Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue
Mar, 2026

(3 years from now)

IN200705107P1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546A1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839A2 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8579869 NOVO Needle mounting system and a method for mounting a needle assembly Jun, 2023

(8 months from now)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly May, 2024

(1 year, 7 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Aug, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display Oct, 2025

(3 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jul, 2026

(3 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism Jul, 2026

(3 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul, 2026

(3 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul, 2026

(3 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen Aug, 2026

(3 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display Feb, 2027

(4 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism Sep, 2027

(4 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen Feb, 2032

(9 years from now)

US10335462 NOVO Use of long-acting GLP-1 peptides Jun, 2033

(10 years from now)

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/1.5ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription
4MG/3ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription

2. Drug name - RYBELSUS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(9 years from now)

CN101133082A NOVO Acylated Glp-1 Compound
Mar, 2026

(3 years from now)

CN101133082B NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

IN262697B NOVO Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue
Mar, 2026

(3 years from now)

IN200705107P1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546A1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839A2 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086047 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Dec, 2031

(9 years from now)

US10960052 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid Dec, 2031

(9 years from now)

US9278123 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Dec, 2031

(9 years from now)

US10933120 NOVO Compositions of GLP-1 peptides and preparation thereof Mar, 2033

(10 years from now)

US10278923 NOVO Oral dosing of GLP-1 compounds May, 2034

(11 years from now)

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

3. Drug name - WEGOVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(9 years from now)

CN101133082A NOVO Acylated Glp-1 Compound
Mar, 2026

(3 years from now)

CN101133082B NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

IN262697B NOVO Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue
Mar, 2026

(3 years from now)

IN200705107P1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546A1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839A2 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides Jun, 2033

(10 years from now)

US10888605 NOVO GLP-1 compositions and uses thereof Aug, 2038

(15 years from now)

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.25MG/0.5ML (0.25MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
0.5MG/0.5ML (0.5MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1MG/0.5ML (1MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1.7MG/0.75ML (1.7MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription
2.4MG/0.75ML (2.4MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.